Solmaz AghaAmiri, PhD
The University of Texas Health Science Center at Houston
NTIG

The North American Neuroendocrine Tumor Society (NANETS) congratulates Solmaz AghaAmiri, PhD, Post-Doctoral Researcher, The University of Texas Health Science Center at Houston (UTHealth), as the 2022 recipient of NANETS Theranostics Investigator Grant (NTIG). Dr. AghaAmiri was awarded this scholarship for her proposal: Overcoming MGMT resistance in NETs with a tumor-targeted drug conjugate.

Dr, AghaAmiri will be mentored by Dr. Ali Azhdarinia (Associate Professor, McGovern Medical School at the University of Texas Health Science Center at Houston (UTHealth), and Center for Translational Cancer Research at the Institute of Molecular Medicine) and Daniel Halperin, MD, medical oncologist, MD Anderson Cancer Center and NANETS board member.

The NTIG award is a two-year, $100,000 grant made possible through generous support from the North American Neuroendocrine Tumor Society (NANETS) and supported by an educational grant from Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications.

Vineeth Sukrithan, MD
The Ohio State University
NCIS

The North American Neuroendocrine Tumor Society (NANETS) congratulates Vineeth Sukrithan, MD, Assistant Professor of Medicine, The Ohio State University, as the 2022 recipient of the NANETS Clinical Investigator Scholarship (NCIS). Dr. Sukrithan as awarded the NCIS for his proposal: The Role of LAG-3 and its Ligands in Neuroendocrine Tumors Treated with Immunotherapy.

The NCIS is a $100,000 two-year award made possible by the support of Ipsen Biopharmaceuticals, a long-time supporter of NANETS’ educational events and research.

Eleonora Pelle, MD
Moffitt Cancer Center
BTSI

The North American Neuroendocrine Tumor Society (NANETS) congratulates Eleonora Pelle, MD, Post-
Doctoral Researcher, Moffitt Cancer Center, Tampa, FL, as the 2022 recipient of NANETS’ Basic/Translational Science Investigator Award (BTSI). Dr. Pelle was awarded this scholarship for her proposal: Development of a Novel Anti-SSTR Bispecific T-cell Engager (BiTE)-like Molecule for the Treatment of Neuroendocrine Tumors (NETs).

The BTSI award is a two-year, $100,000 grant made possible through generous support from the
Neuroendocrine Tumor Research Foundation (NETRF). The purpose of the BTSI Award is to encourage
scientists at the end of their fellowship who have secured a faculty appointment or scientists beginning
their faculty appointment to pursue research focused on neuroendocrine tumors.